Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 275

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 275
---
                                     |     | 2023 |   Year Ended 
 December 31, |     | 2022 |       |     | 2024 | Nine Months Ended 
     September 30, |     | 2023 |       |
|:------------------------------------|:----|:-----|-------------:|:----|:-----|------:|:----|:-----|------------------:|:----|:-----|------:|
| Selling, general and administrative |     | $    |        7,450 |     | $    | 6,333 |     | $    |             5,704 |     | $    | 5,417 |
| Research and development            |     |      |        4,504 |     |      | 3,310 |     |      |             3,281 |     |      | 3,281 |
| Total                               |     | $    |       11,954 |     | $    | 9,643 |     | $    |             8,985 |     | $    | 8,843 |

As of December 31, 2023, total unamortized share-basedcompensation was $25.3 million which we expect to recognize over a weighted average period of 2.5 years. As of December 31, 2023, there was $0.1 million of unrecognized compensation cost related to restricted stock units, which is expected to be recognized over a weighted average period of nine months. The intrinsic value of all outstanding stock options as of December 31, 2023 was $24,900. As of September 30, 2024 there was $0.5 million of unrecognized compensation cost related to restricted stock units, which is expected to be recognized over a weighted average period of 3.4 years. As of September 30, 2024, there was $14.5 million of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted average period of 1.9 years. Recent Accounting Pronouncements See Note 2 to the consolidated audited financial statements and the related notes thereto included elsewhere in this proxy statement for a discussion of recent accounting pronouncements. - 195 -

THE FYARRO BUSINESS

References in the following discussion to “we,” “our,” “us,” or “Aadi” refer to Aadi Bioscience, Inc. and its subsidiaries.

Throughout this section we refer to FY